Moderator: SABCS Co-director Virginia Kaklamani, MD, leader of the Breast Cancer Program at UT Health San Antonio

Abstracts are appended to the bottom of each news release (WEBCASTS at the bottom):

Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women

ABSTRACT Publication Number: GS5-00 Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's health initiative randomized trials

Rowan T Chlebowski, Garnet L Anderson, Aaron K Aragaki, JoAnn E Manson, et al. SLIDES

Conclusions: CEE-alone and CEE plus MPA use have opposite effects on breast cancer incidence. CEE alone significantly decreases breast cancer incidence which is long term and persists over a decade after discontinuing use. CEE plus MPAuse significantly increases breast cancer incidence which is long term and persists over a decade after discontinuing use. As a result of the attenuation of subgroup interactions: all postmenopausal women with prior hysterectomy using CEE-alone have the potential benefit of experiencing a reduction in breast cancer incidence while all postmenopausal women using CEE plus MPA have the potential risk of experiencing an increase in breast cancer incidence.

 

Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type:

ABSTRACT Publication Number: GS5-01 Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer: A multi-center pooled analysis

Christina Yau, Marieke van der Noordaa, Jane Wei, Marie Osdoit, et al. SLIDES

Conclusions: While not all cancer centers routinely collect data on residual cancer burden, this analysis shows that pathologists can implement it with accurate results, adding to its potential as a predictor of recurrence within breast cancer subtypes.

 

Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple Negative Breast Cancer:

ABSTRACT Publication Number: GS5-02 Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158

Milan Radovich, Guanglong Jiang, Christopher Chitambar, Rita Nanda, et al. SLIDES

Conclusions: Detection of ctDNA in early-stage TNBC after neoadjuvant chemotherapy is an independent predictor of disease recurrence, and represents an important novel stratification factor for future post-neoadjuvant trials.

 

Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial:

ABSTRACT Publication Number: GS6-01 Oral paclitaxel with encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: A phase III clinical study in metastatic breast cancer

David L Cutler, Gerardo Umanzor, Francisco J Barrios, Rosa H Vassallo, et al. SLIDES

Conclusion: Oral paclitaxel + encequidar is the first orally administered paclitaxel shown to be superior to IV paclitaxel for confirmed response, progression-free survival, and overall survival, with minimal clinically meaningful neuropathy.